149 related articles for article (PubMed ID: 26319618)
1. Calretinin is expressed in the stroma of adamantinomatous craniopharyngioma and may induce calcification.
Chaohu W; Yi L; Hai H; Hui Z; Jun P; Song-Tao Q
Clin Neurol Neurosurg; 2015 Nov; 138():124-8. PubMed ID: 26319618
[TBL] [Abstract][Full Text] [Related]
2. Does the calcification of adamantinomatous craniopharyngioma resemble the calcium deposition of osteogenesis/odontogenesis?
Song-Tao Q; Xiao-Rong Y; Jun P; Yong-Jian D; Jin L; Guang-Long H; Yun-Tao L; Jian R; Xiang-Zhao L; Jia-Ming X
Histopathology; 2014 Feb; 64(3):336-47. PubMed ID: 24387671
[TBL] [Abstract][Full Text] [Related]
3. Osteoblastic differentiation and cell calcification of adamantinomatous craniopharyngioma induced by bone morphogenetic protein-2.
Yan X; Kang D; Pan J; Jiang C; Lin Y; Qi S
Cancer Biomark; 2017; 18(2):191-198. PubMed ID: 27983534
[TBL] [Abstract][Full Text] [Related]
4. Interleukin‑6 induces an epithelial‑mesenchymal transition phenotype in human adamantinomatous craniopharyngioma cells and promotes tumor cell migration.
Zhou J; Zhang C; Pan J; Chen L; Qi ST
Mol Med Rep; 2017 Jun; 15(6):4123-4131. PubMed ID: 28487953
[TBL] [Abstract][Full Text] [Related]
5. Drug priming enhances radiosensitivity of adamantinomatous craniopharyngioma via downregulation of survivin.
Stache C; Bils C; Fahlbusch R; Flitsch J; Buchfelder M; Stefanits H; Czech T; Gaipl U; Frey B; Buslei R; Hölsken A
Neurosurg Focus; 2016 Dec; 41(6):E14. PubMed ID: 27903123
[TBL] [Abstract][Full Text] [Related]
6. Differential Expression of Stem Cell Markers in Human Adamantinomatous Craniopharyngioma and Pituitary Adenoma.
Chang CV; Araujo RV; Cirqueira CS; Cani CM; Matushita H; Cescato VA; Fragoso MC; Bronstein MD; Zerbini MC; Mendonca BB; Carvalho LR
Neuroendocrinology; 2017; 104(2):183-193. PubMed ID: 27161333
[TBL] [Abstract][Full Text] [Related]
7. Growth patterns of craniopharyngiomas: clinical analysis of 226 patients.
Pan J; Qi S; Liu Y; Lu Y; Peng J; Zhang X; Xu Y; Huang GL; Fan J
J Neurosurg Pediatr; 2016 Apr; 17(4):418-33. PubMed ID: 26636252
[TBL] [Abstract][Full Text] [Related]
8. CBX4-dependent regulation of HDAC3 nuclear translocation reduces Bmp2-induced osteoblastic differentiation and calcification in adamantinomatous craniopharyngioma.
Yan X; Kang D; Lin Y; Qi S; Jiang C
Cell Commun Signal; 2022 Jan; 20(1):3. PubMed ID: 34980138
[TBL] [Abstract][Full Text] [Related]
9. Immunohistochemistry or Molecular Analysis: Which Method Is Better for Subtyping Craniopharyngioma?
Fukuhara N; Iwata T; Inoshita N; Yoshimoto K; Kitagawa M; Fukuhara H; Tatsushima K; Yamaguchi-Okada M; Takeshita A; Ito J; Takeuchi Y; Yamada S; Nishioka H
Endocr Pathol; 2021 Jun; 32(2):262-268. PubMed ID: 32965631
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical expression of ErbB2 in adamantinomatous craniopharyngiomas: a possible target for immunotherapy.
Zuhur SS; Tanik C; Erol RS; Musluman AM; Kabukcuoglu F; Altuntas Y
Turk Neurosurg; 2013; 23(1):55-60. PubMed ID: 23344868
[TBL] [Abstract][Full Text] [Related]
11. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
Esheba GE; Hassan AA
J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
[TBL] [Abstract][Full Text] [Related]
12. Papillary craniopharyngioma: a clinicopathological study of 48 cases.
Crotty TB; Scheithauer BW; Young WF; Davis DH; Shaw EG; Miller GM; Burger PC
J Neurosurg; 1995 Aug; 83(2):206-14. PubMed ID: 7616262
[TBL] [Abstract][Full Text] [Related]
13. The relationship of adamantinomatous craniopharyngioma to ghost cell ameloblastoma of the jaws: a histopathologic and immunohistochemical study.
Badger KV; Gardner DG
J Oral Pathol Med; 1997 Sep; 26(8):349-55. PubMed ID: 9379423
[TBL] [Abstract][Full Text] [Related]
14. Expression of aberrant beta-catenin and impaired p63 in craniopharyngiomas.
Cao J; Lin JP; Yang LX; Chen K; Huang ZS
Br J Neurosurg; 2010 Jun; 24(3):249-56. PubMed ID: 20128632
[TBL] [Abstract][Full Text] [Related]
15. Tight junction protein claudin-1 is differentially expressed in craniopharyngioma subtypes and indicates invasive tumor growth.
Stache C; Hölsken A; Fahlbusch R; Flitsch J; Schlaffer SM; Buchfelder M; Buslei R
Neuro Oncol; 2014 Jan; 16(2):256-64. PubMed ID: 24305709
[TBL] [Abstract][Full Text] [Related]
16. Genomic Alterations of Adamantinomatous and Papillary Craniopharyngioma.
Goschzik T; Gessi M; Dreschmann V; Gebhardt U; Wang L; Yamaguchi S; Wheeler DA; Lauriola L; Lau CC; Müller HL; Pietsch T
J Neuropathol Exp Neurol; 2017 Feb; 76(2):126-134. PubMed ID: 28069929
[TBL] [Abstract][Full Text] [Related]
17. Xanthogranuloma of the sellar region: a clinicopathological entity different from adamantinomatous craniopharyngioma.
Paulus W; Honegger J; Keyvani K; Fahlbusch R
Acta Neuropathol; 1999 Apr; 97(4):377-82. PubMed ID: 10208277
[TBL] [Abstract][Full Text] [Related]
18. Epithelial-mesenchymal transition and clinicopathological correlation in craniopharyngioma.
Qi ST; Zhou J; Pan J; Zhang C; Silky C; Yan XR
Histopathology; 2012 Oct; 61(4):711-25. PubMed ID: 23551434
[TBL] [Abstract][Full Text] [Related]
19. Periostin activates pathways involved in epithelial-mesenchymal transition in adamantinomatous craniopharyngioma.
Chen M; Zheng SH; Liu Y; Shi J; Qi ST
J Neurol Sci; 2016 Jan; 360():49-54. PubMed ID: 26723972
[TBL] [Abstract][Full Text] [Related]
20. Radiosensitive squamous cell craniopharyngioma: clinical and pathological comparison with the adamantinomatous type.
Inoue HK; Nakamura M; Ono N; Kohga H; Kakegawa T; Naitou I; Tamada J; Handa I
Noshuyo Byori; 1993; 10(1):27-31. PubMed ID: 8220780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
